Valion Bio (VIBO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Jul, 2026Executive summary
Special Meeting scheduled for August 14, 2026, to be held virtually, with voting available online, by phone, or by mail.
Only holders of common stock as of the record date are entitled to vote; preferred stockholders have no voting rights for this meeting.
Board recommends voting FOR both proposals: reverse stock split authorization and adjournment authority.
Voting matters and shareholder proposals
Proposal 1 seeks approval for a reverse stock split at a ratio between 1-for-5 and 1-for-50, at the Board's discretion within twelve months of approval.
Proposal 2 authorizes the Board to adjourn the meeting to solicit additional proxies if needed.
Both proposals require a majority of shares present or represented by proxy to pass; abstentions count as votes against.
No dissenters' rights are available for either proposal.
Advance notice procedures for shareholder proposals and director nominations for the 2027 annual meeting are outlined.
Board of directors and corporate governance
Board has authority to determine the reverse split ratio and may abandon the split at its discretion.
Board has adopted a written related person transaction policy and reviews such transactions through the Audit and Risk Committee.
Latest events from Valion Bio
- Q1 2026 saw higher expenses, net loss, and liquidity risks amid strategic transformation.VIBO
Q1 20268 Jul 2026 - All proposals passed as the company advances its clinical-stage biopharma strategy.VIBO
AGM 20265 Jun 2026 - Shareholders will vote on director election, equity plan, auditor, and major share issuance approvals.VIBO
Proxy filing30 Apr 2026 - Board recommends approval of director, equity plan, auditor, and major share issuance proposals.VIBO
Proxy filing20 Apr 2026 - Late-stage immune therapies advance toward approval, with Entolimod targeting ARS and neutropenia.VIBO
Emerging Growth Conference 9117 Apr 2026 - Biopharma pivots to TLR5 assets, registers 956K shares for $50M equity line with Tumim.VIBO
Registration filing13 Apr 2026 - Shifted to immunotherapy, expanded manufacturing, and improved cash position despite higher losses.VIBO
Q4 202525 Mar 2026 - Acquisition of manufacturing assets and Velocity Bioworks launch drive strategic transformation.VIBO
EGM 202612 Mar 2026 - Advancing late-stage biologics for radiation and oncology with major milestones ahead.VIBO
Investor presentation12 Mar 2026